News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Amol Akhade: Do we need phase 3 clinical trials for oncology drug approvals?
Amol Akhade/hiranandanihospital.org
Jan 24, 2025, 14:12

Amol Akhade: Do we need phase 3 clinical trials for oncology drug approvals?

Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on LinkedIn about his recent editorial published in Indian Journal of Cancer:

“My Editorial published in Indian Journal of Cancer.

Do we need Phase 3 Clinical trials for oncology drug approvals?

Do read and comment.

Last line is my favorite.

Remember, just like for life in general, barring few exceptions, there are no shortcuts to any place worth going.”

“Do we need phase 3 randomized clinical trials for oncology drug approvals?”

Author: Amol Akhade

Amol Akhade: Do we need phase 3 clinical trials for oncology drug approvals?

More posts featuring Amol Akhade.

Amol Akhade cancer Indian Journal of Cancer OncoDaily Oncology oncology drug approvals
Special Coverage
Blog
Jun 3, 2025, 11:29
Bar Levy: ASCO 2025 - Latest Gynecologic Cancer Abstracts and Public Health and Patient Advocacy perspective
Blog
Jun 3, 2025, 11:20
Stephen V Liu: Randomized Phase 3 Trial of Time of Day of Immunotherapy Infusion
Insight
Jun 3, 2025, 11:15
Armando Orlandi: Day 4 at ASCO 2025 - Key Breast Cancer Clinical Advances 
Blog
Jun 3, 2025, 11:14
Jeff Ryckman Promoted to Associate Professor
Blog
Jun 3, 2025, 11:09
Rafeh Naqash: The Real Star Behind the Scenes who make ASCO a Success Every Year Every Time
Blog
Jun 3, 2025, 10:56
Giannis Mountzios: ASCO25 is About Science, Research, Care but Also Your Second Family - Colleagues and Friends
Blog
Jun 3, 2025, 10:50
Paolo Tarantino: We need Biomarkers to Tailor Treatment with T-DXd
Opinion
Jun 3, 2025, 10:41
TRIgnite-1 study at ASCO 2025 showed High Response Rates and Favorable Safety Profile for the Treatment of Relapsed/Refractory Multiple Myeloma with First-in-Class BCMA × CD38 × CD3 Trispecific Antibody 
Blog
Jun 3, 2025, 10:35
Mario Balsa Shares ASCENT-04 Trial Results in First-Line mTNBC at ASCO25
Blog
Jun 3, 2025, 10:33
Vivek Subbiah: Waiting for ASCO 2025 Hematology Discussions with Naveen Pemmaraju
Blog
Jun 3, 2025, 10:27
Supriya Peshin Reflects on a Memorable Moment with Oncology Colleagues
Blog
Jun 3, 2025, 09:54
Robin Zon: ASCO 2025 President’s Address - “Driving Knowledge to Action: Building a Better Future”